vs
ベクトン・ディキンソン（BDX）とFidelity National Information Services（FIS）の財務データ比較。上の社名をクリックして会社を切り替えられます
ベクトン・ディキンソンの直近四半期売上が大きい（$5.3B vs $2.8B、Fidelity National Information Servicesの約1.9倍）。Fidelity National Information Servicesの純利益率が高く（18.2% vs 7.3%、差は10.9%）。Fidelity National Information Servicesの前年同期比売上増加率が高い（8.1% vs -0.4%）。Fidelity National Information Servicesの直近四半期フリーキャッシュフローが多い（$739.0M vs $549.0M）。過去8四半期でFidelity National Information Servicesの売上複合成長率が高い（6.8% vs 2.0%）
ベクトン・ディキンソンは米国発の多国籍医療テクノロジー企業で、医療機器、計測システム、試薬の製造・販売を行っているほか、特定の分野でコンサルティングや分析サービスも提供し、グローバルに事業を展開している。
Fidelity National Information Services（FIS）は米国発の多国籍企業で、金融テクノロジー分野を主力として多様な金融商品・サービスを提供しています。年間約750億件の取引を処理し、約9兆米ドルの資金移動を支援し、世界2万社以上の顧客にサービスを展開しています。
BDX vs FIS — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $5.3B | $2.8B |
| 純利益 | $382.0M | $511.0M |
| 粗利率 | 45.9% | 38.3% |
| 営業利益率 | 10.5% | 18.8% |
| 純利益率 | 7.3% | 18.2% |
| 売上前年比 | -0.4% | 8.1% |
| 純利益前年比 | 24.0% | 97.3% |
| EPS（希薄化後） | $1.34 | $0.98 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $5.3B | $2.8B | ||
| Q3 25 | $5.9B | $2.7B | ||
| Q2 25 | $5.5B | $2.6B | ||
| Q1 25 | $5.3B | $2.5B | ||
| Q4 24 | $5.2B | $2.6B | ||
| Q3 24 | $5.4B | $2.6B | ||
| Q2 24 | $5.0B | $2.5B | ||
| Q1 24 | $5.0B | $2.5B |
| Q4 25 | $382.0M | $511.0M | ||
| Q3 25 | $493.0M | $264.0M | ||
| Q2 25 | $574.0M | $-470.0M | ||
| Q1 25 | $308.0M | $77.0M | ||
| Q4 24 | $303.0M | $259.0M | ||
| Q3 24 | $400.0M | $224.0M | ||
| Q2 24 | $487.0M | $243.0M | ||
| Q1 24 | $537.0M | $724.0M |
| Q4 25 | 45.9% | 38.3% | ||
| Q3 25 | 47.5% | 37.8% | ||
| Q2 25 | 47.8% | 36.4% | ||
| Q1 25 | 42.8% | 34.7% | ||
| Q4 24 | 43.2% | 36.9% | ||
| Q3 24 | 45.7% | 38.0% | ||
| Q2 24 | 46.2% | 38.2% | ||
| Q1 24 | 45.7% | 37.1% |
| Q4 25 | 10.5% | 18.8% | ||
| Q3 25 | 11.8% | 16.8% | ||
| Q2 25 | 16.0% | 15.6% | ||
| Q1 25 | 10.4% | 13.7% | ||
| Q4 24 | 8.8% | 18.5% | ||
| Q3 24 | 11.4% | 19.1% | ||
| Q2 24 | 12.1% | 15.2% | ||
| Q1 24 | 14.5% | 14.6% |
| Q4 25 | 7.3% | 18.2% | ||
| Q3 25 | 8.4% | 9.7% | ||
| Q2 25 | 10.4% | -18.0% | ||
| Q1 25 | 5.8% | 3.0% | ||
| Q4 24 | 5.9% | 10.0% | ||
| Q3 24 | 7.4% | 8.7% | ||
| Q2 24 | 9.8% | 9.8% | ||
| Q1 24 | 10.6% | 29.3% |
| Q4 25 | $1.34 | $0.98 | ||
| Q3 25 | $1.71 | $0.50 | ||
| Q2 25 | $2.00 | $-0.90 | ||
| Q1 25 | $1.07 | $0.15 | ||
| Q4 24 | $1.04 | $0.51 | ||
| Q3 24 | $1.37 | $0.41 | ||
| Q2 24 | $1.68 | $0.44 | ||
| Q1 24 | $1.85 | $1.25 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $740.0M | $599.0M |
| 総負債低いほど良い | — | $9.1B |
| 株主資本純資産 | $25.3B | $13.9B |
| 総資産 | $54.8B | $33.5B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.65× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $740.0M | $599.0M | ||
| Q3 25 | $641.0M | $571.0M | ||
| Q2 25 | $735.0M | $581.0M | ||
| Q1 25 | $667.0M | $805.0M | ||
| Q4 24 | $711.0M | $834.0M | ||
| Q3 24 | $1.7B | $1.3B | ||
| Q2 24 | $4.5B | $2.1B | ||
| Q1 24 | $2.3B | $3.3B |
| Q4 25 | — | $9.1B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $8.7B | ||
| Q4 24 | — | $9.7B | ||
| Q3 24 | — | $10.5B | ||
| Q2 24 | — | $10.6B | ||
| Q1 24 | — | $10.6B |
| Q4 25 | $25.3B | $13.9B | ||
| Q3 25 | $25.4B | $13.9B | ||
| Q2 25 | $25.5B | $14.2B | ||
| Q1 25 | $25.2B | $15.1B | ||
| Q4 24 | $25.2B | $15.7B | ||
| Q3 24 | $25.9B | $16.6B | ||
| Q2 24 | $25.9B | $17.0B | ||
| Q1 24 | $25.6B | $18.0B |
| Q4 25 | $54.8B | $33.5B | ||
| Q3 25 | $55.3B | $33.0B | ||
| Q2 25 | $54.9B | $33.4B | ||
| Q1 25 | $54.5B | $32.8B | ||
| Q4 24 | $54.7B | $33.8B | ||
| Q3 24 | $57.3B | $34.3B | ||
| Q2 24 | $55.6B | $34.6B | ||
| Q1 24 | $54.2B | $35.9B |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 0.64× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.57× | ||
| Q4 24 | — | 0.62× | ||
| Q3 24 | — | 0.63× | ||
| Q2 24 | — | 0.62× | ||
| Q1 24 | — | 0.59× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $657.0M | $758.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $549.0M | $739.0M |
| FCFマージンFCF / 売上 | 10.5% | 26.3% |
| 設備投資強度設備投資 / 売上 | 2.1% | 0.7% |
| キャッシュ転換率営業CF / 純利益 | 1.72× | 1.48× |
| 直近12ヶ月FCF直近4四半期 | $2.6B | $2.5B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $657.0M | $758.0M | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | $1.2B | $382.0M | ||
| Q1 25 | $164.0M | $457.0M | ||
| Q4 24 | $693.0M | $782.0M | ||
| Q3 24 | $1.2B | $641.0M | ||
| Q2 24 | $1.3B | $546.0M | ||
| Q1 24 | $514.0M | $206.0M |
| Q4 25 | $549.0M | $739.0M | ||
| Q3 25 | $1.0B | $952.0M | ||
| Q2 25 | $1.0B | $343.0M | ||
| Q1 25 | $35.0M | $420.0M | ||
| Q4 24 | $588.0M | $764.0M | ||
| Q3 24 | $882.0M | $605.0M | ||
| Q2 24 | $1.1B | $530.0M | ||
| Q1 24 | $380.0M | $179.0M |
| Q4 25 | 10.5% | 26.3% | ||
| Q3 25 | 17.0% | 35.0% | ||
| Q2 25 | 19.0% | 13.1% | ||
| Q1 25 | 0.7% | 16.6% | ||
| Q4 24 | 11.4% | 29.4% | ||
| Q3 24 | 16.2% | 23.5% | ||
| Q2 24 | 22.4% | 21.3% | ||
| Q1 24 | 7.5% | 7.3% |
| Q4 25 | 2.1% | 0.7% | ||
| Q3 25 | 6.0% | 2.2% | ||
| Q2 25 | 3.2% | 1.5% | ||
| Q1 25 | 2.4% | 1.5% | ||
| Q4 24 | 2.0% | 0.7% | ||
| Q3 24 | 5.4% | 1.4% | ||
| Q2 24 | 3.6% | 0.6% | ||
| Q1 24 | 2.7% | 1.1% |
| Q4 25 | 1.72× | 1.48× | ||
| Q3 25 | 2.75× | 3.83× | ||
| Q2 25 | 2.12× | — | ||
| Q1 25 | 0.53× | 5.94× | ||
| Q4 24 | 2.29× | 3.02× | ||
| Q3 24 | 2.94× | 2.86× | ||
| Q2 24 | 2.66× | 2.25× | ||
| Q1 24 | 0.96× | 0.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
FIS
| Banking Solutions | $1.6B | 57% |
| Other | $701.0M | 25% |
| Capital Market Solutions | $508.0M | 18% |
